Bibliografia
Bibliografia
  1. Myeloma;2019;1-40; Myeloma An Introduction Myeloma Essentials (v1.0). Disponibile a: https://www.myeloma.org.uk/documents/myeloma-an-introduction. Ultimo accesso: maggio 2021. 
  2. Myeloma.org.uk;2019;1-94; Infopack for newly diagnosed myeloma patients (v1.0). Disponibile a: https://www.myeloma.org.uk/documents/infopack-for-newly-diagnosed-patients. Ultimo accesso: maggio 2021.
  3. G.M. Durie B; International Myeloma Foundation;2018;1-28 (v1.0). Disponibile a: https://www.myeloma.org/sites/default/files/resource/ConciseReview.pdf. Ultimo accesso maggio 2021. 
  4. Cowan AJ, et al. Global burden of multiple myeloma. JAMA Oncol. 2018;4(9):1221-1227. 
  5. International Myeloma Foundation;2019;1-6; What is multiple myeloma? (v1.0). Disponibile a: https://www.myeloma.org/what-is-multiple-myeloma. Ultimo accesso maggio 2021.
  6. Kazandjian D, Landgren O. A look back and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016; 43(6):682-689.
  7. Kyle RA, Rajkumar SV. Blood 2008.
  8. ESMO/ACF Patient Guide Series 2017. Disponibile a: https://www.esmo.org/content/download/104831/1843409/1. Ultimo accesso maggio 2021. 
  9. Mayo Clinic; 2018;1-6; Acute kidney failure (v1.0). Disponibile a: https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048. Ultimo accesso maggio 2021.
  10. Cancer Research UK Types of Myeloma. Disponibile a: https://www.cancerresearchuk.org/about-cancer/myeloma/types. Ultimo accesso maggio 2021.
  11. Moreau P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. 
  12. Chim CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262. 
  13. American Society of Clinical Oncology. Multiple myeloma: types of treatment. Disponibile a: https://www.cancer.net/cancer-types/multiple-myeloma/types-treatment. Pubblicato luglio 2018. Ultimo accesso maggio 2021.
  14. Cancer Research Institute. Multiple myeloma clinical trial targets. Disponibile a: https://www.cancerresearch.org/immunotherapy/cancer-types/multiple-myeloma. Ultimo accesso maggio 2021.
  15. Sondergeld P, et al. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9):599-609.
  16. Empliciti Summary of Product Characteristics. Ottobre 2019.
  17. Costa F, et al. Checkpoint inhibition in myeloma: opportunities and challenges. Front Immunol. 2018;9:2204.
  18. Revlimid Summary of Product Characteristics. Gennaio 2017.
  19. Imnovid Summary of Product Characteristics. Luglio 2018.
  20. Thalidomide Celgene Summary of Product Characteristics. Gennaio 2018.
  21. Myeloma Patients Europe. Panobinostat. Disponibile a: https://www.mpeurope.org/what-we-do/publications/factsheets/panobinostat. Ultimo accesso maggio 2021.
  22. National Cancer Institute: SEER Training Modules. Types of chemotherapy drugs. Disponibile a: https://training.seer.cancer.gov/treatment/chemotherapy/types.html. Ultimo accesso maggio 2021.
  23. Bendamustine Hydrochloride Summary of Product Characteristics. Gennaio 2019.
  24. Drugs.com. Melphalan. Disponibile a: https://www.drugs.com/international/melphalan.html. Ultimo accesso maggio 2021.
  25. European Medicines Agency. Levact. Disponibile a: https://www.ema.europa.eu/en/medicines/human/referrals/levact. Ultimo accesso maggio 2021.
  26. Cyclophosphamide Summary of Product Characteristics. Giunio 2017. 
  27. Melphalan Summary of Product Characteristics. Marzo 2014. 
  28. Mateos MV et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018;378(6):518-528.
  29. Facon T et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019;380(22):2104-2115.
  30. Cho SF, et al. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.
  31. Mortara L, et al. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol. 2018;9:2905.
  32. Zah E, et al. T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498-508. 
  33. Flavell L. NY-ESO TCR. Disponibile a: https://immuno-oncologynews.com/ny-eso-tcr. Ultimo accesso maggio 2021.
  34. Melão A. Investigational cancer vaccine galinpepimut-S receives orphan drug status in EU for multiple myeloma. Disponibile a: https://myelomaresearchnews.com/2018/09/24/galinpepimut-s-receives-eu-orphan-drug-status-multiple-myeloma. Pubblicato settembre 24, 2018. Ultimo accesso maggio 2021.
  35. Arends, J et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2016
  36. Myeloma Patients Europe. Caring For Yourself. Disponibile a: https://www.mpeurope.org/about-myeloma/419-2/. Ultimo accesso maggio 2021.
  37. American Society of Clinical Oncology. Managing stress. Disponibile a: https://www.cancer.net/coping-with-cancer/managing-emotions/managing-stress. Pubblicato luglio 2019. Ultimo accesso maggio 2021. 
  38. American Society of Clinical Oncology. Coping with uncertainty. Disponibile a: https://www.cancer.net/coping-with-cancer/managing-emotions/coping-with-uncertainty. Pubblicato aprile 2019. Ultimo accesso maggio 2021.
  39. American Society of Clinical Oncology. Caregivers taking care of themselves. Disponibile a: https://www.cancer.net/coping-with-cancer/caring-loved-one/caregivers-taking-care-themselves. Pubblicato settembre 2019. Ultimo accesso maggio 2021.
  40. Al-Farsi K. Oman Med J. 2013;28(1):3-11;
  41. Smith D, Yong K. BMJ. 2013;346:f3863;
  42. Comert M et al. Turk J Haematol.2013;30(3):234-246;
  43. Vallet S et al. Pharmaceutics. 2018;10(4):202.

Prendersi cura di sè

  1. Aiom, Assistenza psico-sociale dei malati oncologici, 2019, https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_Psicosociali.pdf
  2. Carlson LE, “Mindfulness-based interventions for coping with cancer”. Ann N Y Acad Sci. 2016 Jun;1373(1):5-12. doi: 10.1111/nyas.13029. Epub 2016 Mar 9. PMID: 26963792.
  3. de Vries M, Stiefel F, “Psychotherapy in the Oncology Setting!”. Recent Results Cancer Res. 2018;210:145-161. doi: 10.1007/978-3-319-64310-6_9. PMID: 28924684.
  4. Istituto Toscano Tumori, Psiconcologia, Percorsi, strumenti, prospettive di ricerca, https://www.siponazionale.it/Eventi_pdf_2010/psiconcologia%20pubblicazione.pdf
  5. Lattanzi M, “Psiconcologia: affrontare la malattia oncologica”, State of Mind, https://www.stateofmind.it/2015/05/psiconcologia-affrontare-malattia-oncologica/
  6. Okuyama T et al, “Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis”. Cancer Treat Rev. 2017 May;56:16-27. doi: 10.1016/j.ctrv.2017.03.012. Epub 2017 Apr 11. PMID: 28453966.
  7. Osservatorio Psicologia in Cronicità, L’impatto psicologico nelle malattie oncologiche, https://cronicita.ordinepsicologilazio.it/psicologia-e-malattie-oncologiche/limpatto-psicologico-nelle-malattie-oncologiche/
  8. Portigliatti Pomeri A et al, “EMDR in Cancer Patients: A Systematic Review”. Front Psychol. 2021 Jan 18;11:590204. doi: 10.3389/fpsyg.2020.590204. PMID: 33536968; PMCID: PMC7847844.
  9. Zhang MF et al, “Effectiveness of Mindfulness-based Therapy for Reducing Anxiety and Depression in Patients With Cancer: A Meta-analysis”. Medicine (Baltimore). 2015 Nov;94(45):e0897-0. doi: 10.1097/MD.0000000000000897. PMID: 26559246; PMCID: PMC4912240.
  10. Johnson E, Patient Power: Endless Benefits of Yoga for Cancer Patients, Myeloma Crowd, https://www.myelomacrowd.org/patient-power-endless-benefits-of-yoga-for-cancer-patients/
  11. Megan M, Cancer Rehab and Exercise for the Patient with Multiple Myeloma, Aurora Health Care, https://www.lls.org/sites/default/files/chapters/wi/Pdf/WI-Cancer%20Rehab%20and%20Exercise%20in%20the%20treatment%20of%20Myeloma%20Patients%20-%20Molly%20Megan%20MHS%20PT%20CLT.pdf
  12. Servadio M et al, “Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry”. BMJ Support Palliat Care. 2020 Dec;10(4):e35. doi: 10.1136/bmjspcare-2018-001755. Epub 2019 Jun 28. PMID: 31253733.
  13. Smith L et al, “Multiple myeloma and physical activity: a scoping review”. BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576. Erratum in: BMJ Open. 2016;6(2):e009576corr1. PMID: 26614625; PMCID: PMC4663409.
  14. Staying Active and Safe with Multiple Myeloma, Weill Cornell Medicine Myeloma Center, https://www.myelomacenter.org/news/staying-active-and-safe-multiple-myeloma

Mieloma multiplo: la sfida della cronicità

  1. Aiom, Assistenza psico-sociale dei malati oncologici, 2019, https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_Psicosociali.pdf
  2. Carlson LE, “Mindfulness-based interventions for coping with cancer”. Ann N Y Acad Sci. 2016 Jun;1373(1):5-12.doi: 10.1111/nyas.13029. Epub 2016 Mar 9. PMID: 26963792.
  3. Conner TS, “Everyday creative activity as a path to flourishing”, The Journal of Positive Psychology, 13:2, 2018, 181-189, doi: 10.1080/17439760.2016.1257049.
  4. Cos’è il mieloma multiplo? Siamo qui per spiegartelo. Guide ESMO/ACF per il Paziente, Esmo, https://www.esmo.org/content/download/138239/2546645/file/IT-Mieloma-Multiplo-Una-Guida-per-il-Paziente.pdf
  5. de Vries M, Stiefel F, “Psychotherapy in the Oncology Setting!”. Recent Results Cancer Res. 2018;210:145-161.doi: 10.1007/978-3-319-64310-6_9. PMID: 28924684.
  6. Garza-Villarreal EA et al, “Music-Induced Analgesia in Chronic Pain Conditions: A Systematic Review and Meta-Analysis”. Pain Physician. 2017 Nov;20(7):597-610. PMID: 29149141.
  7. Istituto Toscano Tumori, Psiconcologia, Percorsi, strumenti, prospettive di ricerca, https://www.siponazionale.it/Eventi_pdf_2010/psiconcologia%20pubblicazione.pdf
  8. Johnson E, Patient Power: Endless Benefits of Yoga for Cancer Patients, Myeloma Crowd, https://www.myelomacrowd.org/patient-power-endless-benefits-of-yoga-for-cancer-patients/
  9. Lattanzi M, “Psiconcologia: affrontare la malattia oncologica”, State of Mind, https://www.stateofmind.it/2015/05/psiconcologia-affrontare-malattia-oncologica/
  10. Maher K, de Vries K, “An exploration of the lived experiences of individuals with relapsed multiple myeloma”. Eur J Cancer Care (Engl). 2011 Mar;20(2):267-75. doi: 10.1111/j.1365-2354.2010.01234.x. Epub 2010 Oct 18. PMID: 20950368.
  11. Megan M, Cancer Rehab and Exercise for the Patient with Multiple Myeloma, Aurora Health Care, https://www.lls.org/sites/default/files/chapters/wi/Pdf/WICancer%20Rehab%20and%20Exercise%20in%20the%20treatment%20of%20Myeloma%20Patients%20-%20Molly%20Megan%20MHS%20PT%20CLT.pdf
  12. Mieloma ti sfido, Ail, https://www.ail.it/news2/681-mieloma-ti-sfido
  13. Monterosso L et al, “Living With Multiple Myeloma: A Focus Group Study of Unmet Needs and Preferences for Survivorship Care”. J Patient Exp. 2018;5(1):6-15. doi: 10.1177/2374373517715011.
  14. Osservatorio Psicologia in Cronicità, L’impatto psicologico nelle malattie oncologiche, https://cronicita.ordinepsicologilazio.it/psicologia-e-malattie-oncologiche/limpatto-psicologico-nelle-malattie-oncologiche/
  15. Portigliatti Pomeri A et al, “EMDR in Cancer Patients: A Systematic Review”. Front Psychol. 2021 Jan 18;11:590204. doi: 10.3389/fpsyg.2020.590204. PMID: 33536968; PMCID: PMC7847844.
  16. Servadio M et al, “Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry”. BMJ Support Palliat Care. 2020 Dec;10(4):e35. doi: 10.1136/bmjspcare-2018-001755. Epub 2019 Jun 28. PMID: 31253733.
  17. Smith L et al, “Multiple myeloma and physical activity: a scoping review”. BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576. Erratum in: BMJ Open. 2016;6(2):e009576corr1. PMID: 26614625; PMCID: PMC4663409.
  18. Staying Active and Safe with Multiple Myeloma, Weill Cornell Medicine Myeloma Center, https://www.myelomacenter.org/news/staying-active-and-safe-multiple-myeloma
  19. Stephens M et al, “The work of living with a rare cancer: multiple myeloma”. J Adv Nurs. 2014 Dec;70(12):2800-9.doi: 10.1111/jan.12430. Epub 2014 Apr 13. PMID: 24725097.
  20. Zhang MF et al, “Effectiveness of Mindfulness-based Therapy for Reducing Anxiety and Depression in Patients With Cancer: A Meta-analysis”. Medicine (Baltimore). 2015 Nov;94(45):e0897-0. doi: 10.1097/MD.0000000000000897. PMID: 26559246; PMCID: PMC4912240.

Informazioni sul
mieloma multiplo

Read more »

Opzioni di trattamento
e nuovi farmaci

Read more »